Omics Based Clinical Trials Market
Omics Based Clinical Trials Market Analysis By Phase (Phase 1, Phase 2, Phase 3, Phase 4), By Study Design (Interventional, Observational, Expanded Access Studies), By Indication (Oncology, Cardiology, Skin Diseases, Immunology), By Region - Global Insights 2022 to 2032
Analysis of Omics Based Clinical Trials market covering 30 + countries including analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Omics Based Clinical Trials Market Outlook
Newly-released Omics Based Clinical Trials Market analysis report by Fact.MR shows that global sales of Omics Based Clinical Trials Market in 2021 was held at US$ 26.2 Bn. With 8.1%, the projected market growth during 2022 to 2032 is expected to be significantly higher than the historical growth. Interventional Studies is expected to be the highest revenue generating segment, accounting for an absolute dollar opportunity of nearly US$ 26.6 Bn during 2022 to 2032.
Don't Need a Global Report?
save 40%! on Country & Region specific reports
Key Points Covered in Omics Based Clinical Trials Market Survey :
- Market Estimates and Forecasts (2017 to 2032)
- Key Drivers and Restraints Shaping Market Growth
- Segment-wise, Country-wise, and Region-wise Analysis
- Competition Mapping and Benchmarking
- Market Share Analysis
- COVID-19 Impact on Omics Based Clinical Trials Market and How to Navigate
- Recommendation on Key Winning Strategies
Revenue of Omics Based Clinical Trials Markets from 2017 to 2021 Compared to Demand Outlook for 2022 to 2032
As per the Omics Based Clinical Trials Markets research by Fact.MR - a market research and competitive intelligence provider, historically, from 2017 to 2021, market value of the Omics Based Clinical Trials Markets increased at around 8.0% CAGR, wherein, countries such as the US, China, Japan, Germany, and India held significant share in the global market.
The constant surge in demands for Omics-Based Clinical Trials is due to Covid-19 pandemic. The main drivers were rising investment in the pharmaceutical industry by the prominent participants to enhance their productivity, rising demand for omics-based clinical trials, and increasing prevalence of chronic disorders. Owing to this, Omics Based Clinical Trials Markets is projected to grow at a CAGR of 8.1% over the coming 10 years.
- Omics-Based Clinical Trials Market was valued at US$ 26.2 Bn in 2021. Covid 19 emerged as a turning point for Omics Based Clinical Trials Market and it grew at a 7.5% annual pace compared to the previous year 2020, wherein the valuation was US$ 24.2Bn. According to Fact.MR, Omics Based Clinical Trials Market revenue is projected to increase 2.2X times between 2022 and 2032, reaching roughly US$ 61.7 Bn in 2032.
- In terms of Study Design, the sub-segment Interventional Studies accounts for more than 75% of the market.
- In terms of Indication, Oncology, Cardiology and Respiratory Diseases accounted for a combined share of 58.3%.
- North America is the dominant region in Omics Based Clinical Trials Markets with absolute dollar opportunity of US$ 13.4 Bn during the forecast period.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
How the Rising Use of Multi Omics in Research is Making Omni Based Clinical Trials Markets an Essential Component?
Advanced omics technologies, including single-cell omics and multi-omics, are being used to evaluate a variety of cancer immunotherapies. Furthermore, given the precision medicine environment, the expanding use of multi-omics in research, as well as the penetration of contemporary sequencing technologies, is boosting the market.
COVID-19 has caused substantial supply chain lags in the pharmaceutical industry. The pandemic also had impact on omics based clinical trials. Using an integrative investigation of genomic, proteomic, transcriptomic, lipidomic, and metabolomic profiles, a trans-omics landscape for COVID-19 was discovered.
This has created a wide window of opportunity for the market growth. The market for omics-based clinical trials has witnessed a substantial number of consolidations in recent years in the pharmaceutical industry.
To learn more about the COVID-19 virus, several small enterprises have started omics-based clinical trials. There is a growing demand for a pattern shift toward patient classification, if not even personalised care. Complex diseases that urgently required a sound understanding, analysis and effective therapeutic strategies.
Omics-based studies enable development of precision medicine-based data, For instance, DNA sequencing technique is being used to identify genetic material which addresses specific cancer. Besides, technological advancements in omics technologies enable retrieval of comprehensive and holistic data, which includes genome, proteome, transcriptome, and metabolome.
How is Rising Chronic Disease Boosting Growth of Omics Based Clinical Trials Market?
Due to the COVID-19 epidemic, investment in the pharmaceutical business was increased significantly by prominent actors in order to increase their productivity. This also boosted the demand for omics-based clinical trials. With the rising global prevalence and burden of chronic diseases such as cancer, researchers are looking at several biological targets that could serve as biomarkers of clinical risk as well as therapeutic targets.
Omics based clinical, trials has shown to be the most advanced molecular research method. It encompasses all biological sciences fields that conclude with the suffix -omics. Proteomics, genomics, transcriptomics, and metabolomics are only a few of the omics fields. The coronavirus outbreak has hastened the use of new methodologies, models, and technologies in clinical trials, which has boosted market growth.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Which Region is projected to Offer the Largest Opportunity for Omics Based Clinical Trials Market?
Owing to the ease of regulatory compliance, low study costs, growing patient population, and the existence of a few elite clinical institutions acting as sites, Asia-Pacific has become a hotspot for conducting clinical trials. Omics Based Clinical Trials Market revenue is estimated to expand at the fastest rate in APAC between 2022 and 2032, with a projected growth rate of around 9.0%. China's regulatory bodies, for example, are attempting to improve the clinical trial process by shortening the total review and approval procedure.
Country-wise Analysis
Which Country Lies at the CenterStage for Omics Based Clinical Trials Market Revenue?
U.S. had the biggest revenue share of over 35% in 2021. The market is growing due to the increased prevalence of chronic diseases such as cancer and heart disorders. In the U.S., cancer is one of the prominent causes of death. There were around 1,735,350 new cancer diagnoses and 609,640 cancer-related deaths in 2018.
The single-cell multi-OMIC analysis is a revolutionary method that is helping to advance cancer drug research and therapy alternatives. A growing number of biologics, need for new technologies, and the need for tailored medications and orphan drugs are driving the industry ahead.
Furthermore, rising biotechnology and pharmaceutical industry needs has boosted demand for non-invasive equipment, full applications for single-cell multi-omics technologies, and traditional labs, all of which are expected to drive future market expansion.
Category-wise Insights
Why Phase II Segment Dominated over the Other Phases?
In 2021, the phase II segment dominated the market for omics-based clinical trials, accounting for 37.2% of total revenue. Over the forecast period, the overall segment is expected to grow at 7.6% CAGR. This is due to a huge number of ongoing phase II clinical trials.
Phase II clinical trials had the most projects in 2020, and this trend is projected to continue as industry and non-industry sponsors increase their R&D investments. Furthermore, the globalisation of clinical trials, increasing number of industry-sponsored and non-industry-sponsored phase II clinical trials, and the complexity of phase II clinical trials are likely to propel the segment forward.
Which Segment Acquire the Largest Market Share under Study Design?
In 2021, Under Study Design segment the interventional studies category dominated the market for omics-based clinical trials, accounting for 76.4% of total revenue.
Due to growing number of interventional clinical trial designs, the segment is predicted to grow at an annual rate of 8.4% throughout the projection period. Interventional studies are classified according to the intervention being researched, which can be a medication or biologic, a surgical procedure, a behavioural intervention or a device.
Clinicaltrials.gov has a huge number of interventional studies, particularly in oncology. Over the time, there has been a huge increase in the number of interventional studies conducted.
What are the Market Insights about Segment Indication?
In 2021, the oncology segment dominated the market for omics-based clinical trials, accounting for 33.6% of total revenue. During the projected period, the segment is expected to grow at an annual rate of 7.5%. Global cancer incidences are forecast to increase by 50%, and global cancer fatalities are estimated to increase by 60% by 2030, indicating that omics-based clinical trials in this area have a bright future.
How Has COVID-19 Impacted Revenue Generation from Omics Based Clinical Trials Market?
COVID-19 has wreaked havoc on the pharmaceutical industry's supply chain. COVID-19, on the other hand, has produced multiple omics outcomes. A trans-omics landscape for COVID-19 was published based on an integrated investigation of genomic, proteomic, transcriptomic, lipidomic, and metabolomic profiles. As a result, the market has a significant possibility to expand. To further comprehend the COVID-19 virus, several small businesses have begun omics-based clinical trials.
Competitive Analysis
Due to the presence of a large number of developed as well as medium to small-sized organisations, the market for omics-based clinical trials is significantly competitive. A number of market participants are privately held or are part of the portfolios of private equity companies.
Some of the key prominent players in the Omics Based Clinical Trials market include: Parexel International Corporation, Pharmaceutical Product Development (PPD), Charles River Laboratory, ICON plc, SGS SA, Eli Lilly and Company, Pfizer Inc., Covance Inc., Novo Nordisk, Rebus Bio.
Some of the recent developments of key Omics Based Clinical Trials providers are as follows:
- In December 2021, Rebus Biosystems Inc., a life science technology firm based in the U.S., stated that it had acquired the assay assets and IP of EEL Transcriptomics AB, a privately held company focused on high-plex spatial transcriptomics with single-cell resolution.
- In November 2021, ICON plc announced that its Accellacare Site Network had grown in reach and capabilities as a result of new relationships with six research sites in four countries.
- In February 2021, Parexel and Neo Genomics established a strategic alliance in precision medicine with the goal of improving study designs and speeding up patient matching in oncology clinical trials.
- In March 2019, Mission Bio and Labcorp teamed to use single-cell genomics to expedite targeted medication development.
Similarly, recent developments related to companies offering Omics Based Clinical Trials have been tracked by the team at Fact.MR, which are available in the full report.
Omics Based Clinical Trials Market Report Scope
| Attribute | Details |
|---|---|
| Forecast Period | 2022 to 2032 |
| Historical Data Available for | 2017 to 2021 |
| Market Analysis | US$ Bn for Value |
| Key Regions Covered | North America; Latin America; Europe; Asia Pacific; Middle East & Africa |
| Key Countries Covered | United States, Canada, Brazil, Mexico, Germany, U.K., France, Spain, Italy, Russia, China, Japan, South Korea, India, Australia, South Africa, Saudi Arabia, UAE, Israel |
| Key Market Segments Covered | Phase, Study Design, Indication, Region |
| Key Companies Profiled | Parexel International Corporation; Pharmaceutical Product Development (PPD); Charles River Laboratory; ICON plc; SGS SA; Eli Lilly and Company; Pfizer Inc.; Covance Inc.; Rebus Bio |
| Pricing | Available upon Request |
Market Segments Covered in Omics Based Clinical Trials Market Analysis
-
By Phase Type :
- Phase 1
- Phase 2
- Phase 3
- Phase 4
-
By Study Design Type :
- Interventional Studies
- Observational Studies
- Expanded Access Studies
-
By Indication :
- Oncology
- Cardiology
- Respiratory Diseases
- Skin Diseases
- CNS Diseases
- Immunology
- Genetic Diseases
- Other Indications
-
By Region :
- North America
- Latin America
- Europe
- APAC
- MEA
Table of Content
- 1. Executive Summary
- 2. Market Overview
- 3. Market Risks and Trends Assessment
- 4. Market Background
- 5. Key Success Factors
- 6. Global Market Demand Analysis 2017 to 2021 and Forecast, 2022 to 2032
- 7. Global Market Value Analysis 2017 to 2021 and Forecast, 2022 to 2032
- 8. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Phase
- 8.1. Phase I
- 8.2. Phase II
- 8.3. Phase III
- 8.4. Phase IV
- 9. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Study Design
- 9.1. Interventional Studies
- 9.2. Observational Studies
- 9.3. Expanded Access Studies
- 10. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Indication
- 10.1. Oncology
- 10.2. Cardiology
- 10.3. Respiratory Diseases
- 10.4. Skin Diseases
- 10.5. CNS Diseases
- 10.6. Immunology
- 10.7. Genetic Diseases (includes rare diseases)
- 10.8. Other Indications
- 11. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Region
- 11.1. North America
- 11.2. Latin America
- 11.3. Europe
- 11.4. Asia Pacific
- 11.5. Middle East and Africa (MEA)
- 12. North America Market Analysis 2017 to 2021 and Forecast 2022 to 2032
- 13. Latin America Market Analysis 2017 to 2021 and Forecast 2022 to 2032
- 14. Europe Market Analysis 2017 to 2021 and Forecast 2022 to 2032
- 15. Asia Pacific Market Analysis 2017 to 2021 and Forecast 2022 to 2032
- 16. Middle East and Africa Market Analysis 2017 to 2021 and Forecast 2022 to 2032
- 17. Key Countries Market Analysis 2017 to 2021 and Forecast 2022 to 2032
- 18. Market Structure Analysis
- 19. Competition Analysis
- 19.1. Parexel International Corporation
- 19.2. Pharmaceutical Product Development (PPD)
- 19.3. Charles River Laboratory
- 19.4. ICON plc
- 19.5. SGS SA
- 19.6. Eli Lilly and Company
- 19.7. Pfizer Inc.
- 19.8. Covance Inc.
- 19.9. Rebus Bio
- 20. Assumptions and Acronyms Used
- 21. Research Methodology
Don't Need a Global Report?
save 40%! on Country & Region specific reports
List Of Table
Table 1: Global Market Value (US$ Mn), By Phase, 2017 to 2021
Table 2: Global Market Value (US$ Mn), By Phase, 2022 to 2032
Table 3: Global Market Value (US$ Mn), By Indication, 2017 to 2021
Table 4: Global Market Value (US$ Mn), By Indication, 2022 to 2032
Table 5: Global Market Value (US$ Mn), By Study Design, 2017 to 2021
Table 6: Global Market Value (US$ Mn), By Study Design, 2022 to 2032
Table 7: Global Market, By Region, 2017 to 2021
Table 8: Global Market, By Region, 2022 to 2032
Table 9: North America Market Value (US$ Mn), By Phase, 2017 to 2021
Table 10: North America Market Value (US$ Mn), By Phase, 2022 to 2032
Table 11: North America Market Value (US$ Mn), By Indication, 2017 to 2021
Table 12: North America Market Value (US$ Mn), By Indication, 2022 to 2032
Table 13: North America Market Value (US$ Mn), By Study Design, 2017 to 2021
Table 14: North America Market Value (US$ Mn), By Study Design, 2022 to 2032
Table 15: North America Market, By Country, 2017 to 2021
Table 16: North America Market, By Country, 2022 to 2032
Table 17: Latin America Market Value (US$ Mn), By Phase, 2017 to 2021
Table 18: Latin America Market Value (US$ Mn), By Phase, 2022 to 2032
Table 19: Latin America Market Value (US$ Mn), By Indication, 2017 to 2021
Table 20: Latin America Market Value (US$ Mn), By Indication, 2022 to 2032
Table 21: Latin America Market Value (US$ Mn), By Study Design, 2017 to 2021
Table 22: Latin America Market Value (US$ Mn), By Study Design, 2022 to 2032
Table 23: Latin America Market, By Country, 2017 to 2021
Table 24: Latin America Market, By Country, 2022 to 2032
Table 25: Europe Market Value (US$ Mn), By Phase, 2017 to 2021
Table 26: Europe Market Value (US$ Mn), By Phase, 2022 to 2032
Table 27: Europe Market Value (US$ Mn), By Indication, 2017 to 2021
Table 28: Europe Market Value (US$ Mn), By Indication, 2022 to 2032
Table 29: Europe Market Value (US$ Mn), By Study Design, 2017 to 2021
Table 30: Europe Market Value (US$ Mn), By Study Design, 2022 to 2032
Table 31: Europe Market, By Country, 2017 to 2021
Table 32: Europe Market, By Country, 2022 to 2032
Table 33: Asia Pacific Market Value (US$ Mn), By Phase, 2017 to 2021
Table 34: Asia Pacific Market Value (US$ Mn), By Phase, 2022 to 2032
Table 35: Asia Pacific Market Value (US$ Mn), By Indication, 2017 to 2021
Table 36: Asia Pacific Market Value (US$ Mn), By Indication, 2022 to 2032
Table 37: Asia Pacific Market Value (US$ Mn), By Study Design, 2017 to 2021
Table 38: Asia Pacific Market Value (US$ Mn), By Study Design, 2022 to 2032
Table 39: Asia Pacific Market, By Country, 2017 to 2021
Table 40: Asia Pacific Market, By Country, 2022 to 2032
Table 41: MEA Market Value (US$ Mn), By Phase, 2017 to 2021
Table 42: MEA Market Value (US$ Mn), By Phase, 2022 to 2032
Table 43: MEA Market Value (US$ Mn), By Indication, 2017 to 2021
Table 44: MEA Market Value (US$ Mn), By Indication, 2022 to 2032
Table 45: MEA Market Value (US$ Mn), By Study Design, 2017 to 2021
Table 46: MEA Market Value (US$ Mn), By Study Design, 2022 to 2032
Table 47: MEA Market, By Country, 2017 to 2021
Table 48: MEA Market, By Country, 2022 to 2032
Table 49: Global Market Incremental $ Opportunity, By Phase, 2017 to 2021
Table 50: Global Market Incremental $ Opportunity, By Indication, 2022 to 2032
Table 51: Global Market Incremental $ Opportunity, By Study Design, 2017 to 2021
Table 52: Global Market Incremental $ Opportunity, By Region, 2022 to 2032
Table 53: North America Market Incremental $ Opportunity, By Phase, 2017 to 2021
Table 54: North America Market Incremental $ Opportunity, By Indication, 2022 to 2032
Table 55: North America Market Incremental $ Opportunity, By Study Design, 2017 to 2021
Table 56: North America Market Incremental $ Opportunity, By Country, 2022 to 2032
Table 57: Latin America Market Incremental $ Opportunity, By Phase, 2017 to 2021
Table 58: Latin America Market Incremental $ Opportunity, By Indication, 2022 to 2032
Table 59: Latin America Market Incremental $ Opportunity, By Study Design, 2017 to 2021
Table 60: Latin America Market Incremental $ Opportunity, By Country, 2022 to 2032
Table 61: Europe Market Incremental $ Opportunity, By Phase, 2017 to 2021
Table 62: Europe Market Incremental $ Opportunity, By Indication, 2022 to 2032
Table 63: Europe Market Incremental $ Opportunity, By Study Design, 2017 to 2021
Table 64: Europe Market Incremental $ Opportunity, By Country, 2022 to 2032
Table 65: Asia Pacific Market Incremental $ Opportunity, By Phase, 2017 to 2021
Table 66: Asia Pacific Market Incremental $ Opportunity, By Indication, 2022 to 2032
Table 67: Asia Pacific Market Incremental $ Opportunity, By Study Design, 2017 to 2021
Table 68: Asia Pacific Market Incremental $ Opportunity, By Country, 2022 to 2032
Table 69: MEA Market Incremental $ Opportunity, By Phase, 2017 to 2021
Table 70: MEA Market Incremental $ Opportunity, By Indication, 2022 to 2032
Table 71: MEA Market Incremental $ Opportunity, By Study Design, 2017 to 2021
Table 72: MEA Market Incremental $ Opportunity, By Country, 2022 to 2032
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
List Of Figures
Figure 1: Global Market Value (US$ Mn) and Year-on-Year Growth, 2017 to 2032
Figure 2: Global Market Absolute $ Historical Gain (2017 to 2021) and Opportunity (2022 to 2032), US$ Mn
Figure 3: Global Market Share, By Phase, 2022 & 2032
Figure 4: Global Market Y-o-Y Growth Projections, By Phase – 2022 to 2032
Figure 5: Global Market Attractiveness Index, By Phase – 2022 to 2032
Figure 6: Global Market Share, By Indication, 2022 & 2032
Figure 7: Global Market Y-o-Y Growth Projections, By Indication – 2022 to 2032
Figure 8: Global Market Attractiveness Index, By Indication – 2022 to 2032
Figure 9: Global Market Share, By Study Design, 2022 & 2032
Figure 10: Global Market Y-o-Y Growth Projections, By Study Design – 2022 to 2032
Figure 11: Global Market Attractiveness Index, By Study Design – 2022 to 2032
Figure 12: Global Market Share, By Region, 2022 & 2032
Figure 13: Global Market Y-o-Y Growth Projections, By Region – 2022 to 2032
Figure 14: Global Market Attractiveness Index, By Region – 2022 to 2032
Figure 15: North America Market Value (US$ Mn) and Year-on-Year Growth, 2017 to 2032
Figure 16: North America Market Absolute $ Opportunity Historical (2017 to 2021) and Forecast Period (2022 to 2032), US$ Mn
Figure 17: North America Market Share, By Phase, 2022 & 2032
Figure 18: North America Market Y-o-Y Growth Projections, By Phase – 2022 to 2032
Figure 19: North America Market Attractiveness Index, By Phase – 2022 to 2032
Figure 20: North America Market Share, By Indication, 2022 & 2032
Figure 21: North America Market Y-o-Y Growth Projections, By Indication – 2022 to 2032
Figure 22: North America Market Attractiveness Index, By Indication – 2022 to 2032
Figure 23: North America Market Share, By Study Design, 2022 & 2032
Figure 24: North America Market Y-o-Y Growth Projections, By Study Design – 2022 to 2032
Figure 25: North America Market Attractiveness Index, By Study Design – 2022 to 2032
Figure 26: North America Market Share, By Country, 2022 & 2032
Figure 27: North America Market Y-o-Y Growth Projections, By Country – 2022 to 2032
Figure 28: North America Market Attractiveness Index, By Country – 2022 to 2032
Figure 29: Latin America Market Value (US$ Mn) and Year-on-Year Growth, 2017 to 2032
Figure 30: Latin America Market Absolute $ Opportunity Historical (2017 to 2021) and Forecast Period (2022 to 2032), US$ Mn
Figure 31: Latin America Market Share, By Phase, 2022 & 2032
Figure 32: Latin America Market Y-o-Y Growth Projections, By Phase – 2022 to 2032
Figure 33: Latin America Market Attractiveness Index, By Phase – 2022 to 2032
Figure 34: Latin America Market Share, By Indication, 2022 & 2032
Figure 35: Latin America Market Y-o-Y Growth Projections, By Indication – 2022 to 2032
Figure 36: Latin America Market Attractiveness Index, By Indication – 2022 to 2032
Figure 37: Latin America Market Share, By Study Design, 2022 & 2032
Figure 38: Latin America Market Y-o-Y Growth Projections, By Study Design – 2022 to 2032
Figure 39: Latin America Market Attractiveness Index, By Study Design – 2022 to 2032
Figure 40: Latin America Market Share, By Country, 2022 & 2032
Figure 41: Latin America Market Y-o-Y Growth Projections, By Country – 2022 to 2032
Figure 42: Latin America Market Attractiveness Index, By Country – 2022 to 2032
Figure 43: Europe Market Value (US$ Mn) and Year-on-Year Growth, 2017 to 2032
Figure 44: Europe Market Absolute $ Opportunity Historical (2017 to 2021) and Forecast Period (2022 to 2032), US$ Mn
Figure 45: Europe Market Share, By Phase, 2022 & 2032
Figure 46: Europe Market Y-o-Y Growth Projections, By Phase – 2022 to 2032
Figure 47: Europe Market Attractiveness Index, By Phase – 2022 to 2032
Figure 48: Europe Market Share, By Indication, 2022 & 2032
Figure 49: Europe Market Y-o-Y Growth Projections, By Indication – 2022 to 2032
Figure 50: Europe Market Attractiveness Index, By Indication – 2022 to 2032
Figure 51: Europe Market Share, By Study Design, 2022 & 2032
Figure 52: Europe Market Y-o-Y Growth Projections, By Study Design – 2022 to 2032
Figure 53: Europe Market Attractiveness Index, By Study Design – 2022 to 2032
Figure 54: Europe Market Share, By Country, 2022 & 2032
Figure 55: Europe Market Y-o-Y Growth Projections, By Country – 2022 to 2032
Figure 56: Europe Market Attractiveness Index, By Country – 2022 to 2032
Figure 57: MEA Market Value (US$ Mn) and Year-on-Year Growth, 2017 to 2032
Figure 58: MEA Market Absolute $ Opportunity Historical (2017 to 2021) and Forecast Period (2022 to 2032), US$ Mn
Figure 59: MEA Market Share, By Phase, 2022 & 2032
Figure 60: MEA Market Y-o-Y Growth Projections, By Phase – 2022 to 2032
Figure 61: MEA Market Attractiveness Index, By Phase – 2022 to 2032
Figure 62: MEA Market Share, By Indication, 2022 & 2032
Figure 63: MEA Market Y-o-Y Growth Projections, By Indication – 2022 to 2032
Figure 64: MEA Market Attractiveness Index, By Indication – 2022 to 2032
Figure 65: MEA Market Share, By Study Design, 2022 & 2032
Figure 66: MEA Market Y-o-Y Growth Projections, By Study Design – 2022 to 2032
Figure 67: MEA Market Attractiveness Index, By Study Design – 2022 to 2032
Figure 68: MEA Market Share, By Country, 2022 & 2032
Figure 69: MEA Market Y-o-Y Growth Projections, By Country – 2022 to 2032
Figure 70: MEA Market Attractiveness Index, By Country – 2022 to 2032
Figure 71: Asia Pacific Market Value (US$ Mn) and Year-on-Year Growth, 2017 to 2032
Figure 72: Asia Pacific Market Absolute $ Opportunity Historical (2017 to 2021) and Forecast Period (2022 to 2032), US$ Mn
Figure 73: Asia Pacific Market Share, By Phase, 2022 & 2032
Figure 74: Asia Pacific Market Y-o-Y Growth Projections, By Phase – 2022 to 2032
Figure 75: Asia Pacific Market Attractiveness Index, By Phase – 2022 to 2032
Figure 76: Asia Pacific Market Share, By Indication, 2022 & 2032
Figure 77: Asia Pacific Market Y-o-Y Growth Projections, By Indication – 2022 to 2032
Figure 78: Asia Pacific Market Attractiveness Index, By Indication – 2022 to 2032
Figure 79: Asia Pacific Market Share, By Study Design, 2022 & 2032
Figure 80: Asia Pacific Market Y-o-Y Growth Projections, By Study Design – 2022 to 2032
Figure 81: Asia Pacific Market Attractiveness Index, By Study Design – 2022 to 2032
Figure 82: Asia Pacific Market Share, By Country, 2022 & 2032
Figure 83: Asia Pacific Market Y-o-Y Growth Projections, By Country – 2022 to 2032
Figure 84: Asia Pacific Market Attractiveness Index, By Country – 2022 to 2032
Figure 85: US Market Value (US$ Mn) and Forecast, 2022 to 2032
Figure 86: US Market Share, By Phase, 2021
Figure 87: US Market Share, By Indication, 2021
Figure 88: US Market Share, By Study Design, 2021
Figure 89: Canada Market Value (US$ Mn) and Forecast, 2022 to 2032
Figure 90: Canada Market Share, By Phase, 2021
Figure 91: Canada Market Share, By Indication, 2021
Figure 92: Canada Market Share, By Study Design, 2021
Figure 93: Brazil Market Value (US$ Mn) and Forecast, 2022 to 2032
Figure 94: Brazil Market Share, By Phase, 2021
Figure 95: Brazil Market Share, By Indication, 2021
Figure 96: Brazil Market Share, By Study Design, 2021
Figure 97: Mexico Market Value (US$ Mn) and Forecast, 2022 to 2032
Figure 98: Mexico Market Share, By Phase, 2021
Figure 99: Mexico Market Share, By Indication, 2021
Figure 100: Mexico Market Share, By Study Design, 2021
Figure 101: Germany Market Value (US$ Mn) and Forecast, 2022 to 2032
Figure 102: Germany Market Share, By Phase, 2021
Figure 103: Germany Market Share, By Indication, 2021
Figure 104: Germany Market Share, By Study Design, 2021
Figure 105: U.K. Market Value (US$ Mn) and Forecast, 2022 to 2032
Figure 106: U.K. Market Share, By Phase, 2021
Figure 107: U.K. Market Share, By Indication, 2021
Figure 108: U.K. Market Share, By Study Design, 2021
Figure 109: France Market Value (US$ Mn) and Forecast, 2022 to 2032
Figure 110: France Market Share, By Phase, 2021
Figure 111: France Market Share, By Indication, 2021
Figure 112: France Market Share, By Study Design, 2021
Figure 113: Italy Market Value (US$ Mn) and Forecast, 2022 to 2032
Figure 114: Italy Market Share, By Phase, 2021
Figure 115: Italy Market Share, By Indication, 2021
Figure 116: Italy Market Share, By Study Design, 2021
Figure 117: India Market Value (US$ Mn) and Forecast, 2022 to 2032
Figure 118: India Market Share, By Phase, 2021
Figure 119: India Market Share, By Indication, 2021
Figure 120: India Market Share, By Study Design, 2021
Figure 121: Russia Countries Market Value (US$ Mn) and Forecast, 2022 to 2032
Figure 122: Russia Countries Market Share, By Phase, 2021
Figure 123: Russia Countries Market Share, By Indication, 2021
Figure 124: Russia Countries Market Share, By Study Design, 2021
Figure 125: China Market Value (US$ Mn) and Forecast, 2022 to 2032
Figure 126: China Market Share, By Phase, 2021
Figure 127: China Market Share, By Indication, 2021
Figure 128: China Market Share, By Study Design, 2021
Figure 129: Japan Market Value (US$ Mn) and Forecast, 2022 to 2032
Figure 130: Japan Market Share, By Phase, 2021
Figure 131: Japan Market Share, By Indication, 2021
Figure 132: Japan Market Share, By Study Design, 2021
Figure 133: South Korea Market Value (US$ Mn) and Forecast, 2022 to 2032
Figure 134: South Korea Market Share, By Phase, 2021
Figure 135: South Korea Market Share, By Indication, 2021
Figure 136: South Korea Market Share, By Study Design, 2021
Figure 137: Spain Market Value (US$ Mn) and Forecast, 2022 to 2032
Figure 138: Spain Market Share, By Phase, 2021
Figure 139: Spain Market Share, By Indication, 2021
Figure 140: Spain Market Share, By Study Design, 2021
Figure 141: South Africa Market Value (US$ Mn) and Forecast, 2022 to 2032
Figure 142: South Africa Market Share, By Phase, 2021
Figure 143: South Africa Market Share, By Indication, 2021
Figure 144: South Africa Market Share, By Study Design, 2021
Figure 145: Saudi Arabia Market Value (US$ Mn) and Forecast, 2022 to 2032
Figure 146: Saudi Arabia Market Share, By Phase, 2021
Figure 147: Saudi Arabia Market Share, By Indication, 2021
Figure 148: Saudi Arabia Market Share, By Study Design, 2021
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
- FAQs -
How much is the current worth of the Omics Based Clinical Trials Market?
The global Omics Based Clinical Trials market is worth more than US$ 26.2 Bn at present.
What is the sales forecast for Omics Based Clinical Trials Market?
Value of Omics Based Clinical Trials market are projected to increase at a CAGR of around 8.1% during 2022 – 2032.
What was the last 5 year’s market CAGR?
Value of Omics Based Clinical Trials market increased at a CAGR of around 8.0% during 2017 – 2021.
What is a key trend shaping the growth of the market for Omics Based Clinical Trials Market?
One of the key trends in Omics Based Clinical Trials market includes an increase in the number of clinical trials for various therapeutic areas and growing prevalence of chronic disorders such as cancer
What is driving revenue for Omics Based Clinical Trials Market?
Omics Based Clinical Trials revenue is being driven primarily by the Covid 19 pandemic due to which there was tremendous growth in 2020 and Researchers are looking at numerous biological targets that could serve as indicators of the clinical risk
Which are the top 5 countries driving demand for Omics Based Clinical Trials Market?
Top 5 countries driving demand for Omics Based Clinical Trials are the US, China, Japan, Germany, and India.
What is the outlook for the market in North America?
North America accounted for over 40.2% of Omics Based Clinical Trials demand in 2021.
At what percentage is sales of Omics Based Clinical Trials Market going to register growth in Europe?
The European market for Omics Based Clinical Trial market is projected to expand at a CAGR of around 7.7% during 2022 – 2032.
What statistics does South Korea and Japan reveal?
While the market in South Korea is expected to grow at nearly 8.0%, the market in Japan is projected to register a CAGR of nearly 10.1% during 2022 - 2032.
Omics Based Clinical Trials Market